DOI: https://doi.org/10.22263/2312-4156.2016.6.28
Pobyarzhin V.V., Pashinskaya Е.S., Semenov V.M., Dmitrachenko T.I., Shlyakhtunov E.A.
Morphological and physiological characteristics of cancer cells in mammals (literature review)
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2016;15(6):28-40.
Abstract.
Cancer, malignant tumors and neoplasms, oncologic diseases are a general term for a large group of illnesses that can affect any part of the body. Their characteristic feature is the appearance and rapid division of abnormal cells with possible further advection beyond their usual boundaries into other organs and tissues.
The main types of cancer which are most frequently reported include: lung cancer (1,4-1,5 million deaths per year), stomach cancer (740 000 deaths per year), colon cancer (610 000 deaths), liver cancer (700 000 deaths), breast cancer (460 000 deaths). More than 70% of all deaths from malignant neoplasms occurred in low and mean income countries (WHO, 2015).
During the development and the so-called “parasitism” of cancer cells the violations of the integrity of homeostatic processes that support the functioning of the organism are observed. It is characterized by the immunosuppression, ectopic endocrine syndromes development, tumor cells capture of the most important substrates and metabolites (amino acids, lipoproteins, vitamins (groups B and C), antioxidants and glucose). All this is accompanied by the stress influence on the body, morphological manifestations with irreversible consequences on untimely intervention.
Key words: cancer, morphology, physiology, atypicalness, oncoproteins, human being, tumors.
References
1. Ermolenko AE. Etiological classification of tumors and mechanisms of a carcinogenesis. Mat Morfologiia Elektron Matematika Mediko-Biol Zhurn. 2012;1;(vyp 2). Rezhim dostupa: http://www.smolensk.ru/user/sgma/MMORPH/N-34-html/ermolenko/ermolenko.htm. Data dostupa: 25.12.2016. (In Russ.)
2. Pavlov VN, Izmaylov AA, Viktorova TV, Izmaylova SM, Galimzyanov VZ, Akhmadishina LZ. Genetic risk factors of development of cancer of bladder. Eksperim Klin Urologiia. 2010;(2):25-31. (In Russ.)
3. Vayshlya NA. The study of correlations of expression of a tumor protein survivin and its natural inhibitor SMAC and PML: dis ... kand biol nauk: 03.00.03. Moscow, RF; 2009. 100 р. (In Russ.)
4. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000 Dec;19(53):6102-14.
5. Kovaleva OV, Nazarova OR, Matveev VB, Grachev AN. Molecular characteristics of renal cell carcinoma: early diagnosis and therapy prospects. Uspekhi Molekuliar Onkologii. 2014;(2):36-43. (In Russ.)
6. Pleshkan VV, Alekseenko IV, Zinov'yeva M V, Vinogradova TV, Sverdlov ED. Promoters with specific activity in the cancer cells in gene therapy of melanoma. Acta Naturae. 2011;3(2):14-23. (In Russ.)
7. Ulasov IV. The development of adenovirus genetically engineered drug for the treatment of glioblastoma in model systems: dis … d-ra biol nauk: 14.01.12. Moscow, RF; 2015. 255 р. (In Russ.)
8. Zenyukov AS, Borovskaya TF, Stilidi IS, Nikulin MP, Kurpas EKh, Zenyukova TV, et al. The expression of c-erbb-2 (HER2/neu) in cancer of the stomach: clinico-morphological features. Sibir Onkol Zhurn. 2011;(1):5-10. (In Russ.)
9. Bozhok AA, Semiglazov VF, Semiglazov VV, Arzumanov AS, Kletsel AE. Forecast factors at a breast cancer. Sovremen Onkologiia. 2005;7(1):49. (In Russ.)
10. Semiglazov VF, Ivanov VG, Semiglazov VV, Krivorotko PV, Malodusheva AA, Kolarkova VV, Shamina EA, Kochetova IA. Biologically referred (targetny) therapy of a breast cancer. Ros Med Zhurn. 2007;(25):1912. (In Russ.)
11. Bashmakova EE, Krasitskaya VV, Bondar' AA, Frank LA. Identification of single-nucleotide polymorphisms (r160w, R151c, d294h) in the gene melanocortin receptor 1 (mc1r) bioluminescent analysis. Molekuliar Biologiia. 2015;49(6):953-8. doi: http://dx.doi.org/10.7868/S0026898415050031 (In Russ.)
12. Ivanov AV, Malygin AA, Karpova GG. Common features in the organization of binding site ribosomal protein s26e on the coding of its pre-mRNA and 18S rRNA. Molekuliar Biologiia. 2014;48(3):491-9. (In Russ.)
13. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012 Mar;75(3):311-35. doi: http://dx.doi.org/10.1021/np200906s
14. Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A. Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence. Cancer Lett. 2014 May;346(2):206-16. doi: http://dx.doi.org/10.1016/j.canlet.2014.01.016
15. Zhao J, Chen J, Liu T, Fang J, Wan J, Zhao J, et al. Anti-viral effects of urosolic acid on guinea pig cytomegalovirus in vitro. J Huazhong Univ Sci Technolog Med Sci. 2012 Dec;32(6):883-7. doi: http://dx.doi.org/10.1007/s11596-012-1052-0
16. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003 Mar;58(1):73-9.
17. Zhao CH, Xu J, Zhang YQ, Zhao LX, Feng B. Inhibition of human enterovirus 71 replication by pentacyclic triterpenes and their novel synthetic derivative. Chem Pharm Bull (Tokyo). 2014;62(8):764-71.
18. Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, et al. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One. 2011;6(5):e19705. doi: http://dx.doi.org/10.1371/journal.pone.0019705
19. Abreu RM, Ferreira IC, Calhelha RC, Lima RT, Vasconcelos MH, Adega F, et al. Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies. Eur J Med Chem. 2011 Dec;46(12):5800-6. doi: http://dx.doi.org/10.1016/j.ejmech.2011.09.029
20. Alekseev OM, Richardson RT, Alekseev O, O'Rand MG. Analysis of gene expression profiles in HeLa cells in response to overexpression or siRNA-mediated depletion of NASP. Reprod Biol Endocrinol. 2009 May;7:45. doi: http://dx.doi.org/10.1186/1477-7827-7-45
21. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003 Aug;106(1):66-73.
22. Brooks GF, Butel JS, Morse SA. Herpesviruses. In: Brooks GF, Carroll KC, Butel JS, Morse SA. Medical Microbiology. New York: McGraw-Hill; 2007. P. 429-53.
23. Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003;5(2):89-95.
24. Chaudhry MA, Chodosh LA, McKenna WG, Muschel RJ. Gene expression profiling of HeLa cells in G1 or G2 phases. Oncogene. 2002 Mar;21(12):1934-42. doi: http://dx.doi.org/10.1038/sj.onc.1205264
25. Copeland RL Jr, Das JR, Bakare O, Enwerem NM, Berhe S, Hillaire K, et al. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and-independent prostate cancer cell lines. Anticancer Res. 2007 May-Jun;27(3B):1537-46.
26. Draganov M, Murdjeva M, Michailova-Topalska T. McCoy and McCoy-Plovdiv cell lines in experimental and diagnostic practice – past, present and perspectives. J Cult Collect. 2005;4(1):3-16.
27. Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res. 2009 Apr;29(4):1255-62.
28. Fuchs F, Pau G, Kranz D, Sklyar O, Budjan C, Steinbrink S, et al. Clustering phenotype populations by genome-wide RNAi and multiparametric imaging. Mol Syst Biol. 2010 Jun;6:370. doi: http://dx.doi.org/10.1038/msb.2010.25
29. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010 Sep;102(17):1310-21. doi: http://dx.doi.org/10.1093/jnci/djq279
30. Hnilicová J, Hozeifi S, Dušková E, Icha J, Tománková T, Staněk D. Histone deacetylase activity modulates alternative splicing. PLoS One. 2011 Feb;6(2):e16727. doi: http://dx.doi.org/10.1371/journal.pone.0016727
31. Anichkov NM. The doctrine of apoptosis at the present stage. Uchen Zap SPb GMU im akad IP Pavlova. 1999;(Vyp 4):31-40. (In Russ.)
32. Williams GM. Mechanisms of chemical carcinogenesis and application in human cancer risk assessment. Toxicology. 2001 Sep;166(1-2):3-10.
33. Anichkov NM. Biological and morphological aspects of the doctrine of metastasis of malignant tumors. Med Akadem Zhurn. 2003;(1):3-13. (In Russ.)
34. Anichkov NM, Plotnikova NA. On the morphology and classification of the tumor and cancerous lesions of the prostate. Arkh Patologii. 2001;(5):44-50. (In Russ.)
35. Werner M, Becker KF, Keller G, Höfler H. Gastric adenocarcinoma pathomorphology and molecular pathology. J Cancer Res Clin Oncol. 2001 Apr;127(4):207-16.
36. Little JB. Radiation carcinogenesis. Carcinogenesis. 2000 Mar;21(3):397-404.
37. Webb СР, Vande Woude GF. Genes that regulate metastases and angiogenesis. J Neuro-Оncol. 2000;50(1-2):71-87. doi: http://dx.doi.org/10.1023/A:1006466605356
38. Novik AA, Kamilova TA, Tsygan VN. Genetics in clinical medicine. Saint Petersburg, RF: VMedA; 2001. 219 р. (In Russ.)
39. Kraevskiy NA, Smol'yannikov AV, Sarkisov DS, red. Pathoanatomical diagnosis of human tumors: rukovodstvo v 2 t. 4-e izd pererab i dop. Moscow, RF: Meditsina; 1993. (In Russ.)
40. Khudoley VV VV. Carcinogens: characteristics, patterns, action mechanisms. Saint Petersburg, RF: NII Khimii SPbGU; 1999. 419 р. (In Russ.)
41. Arver B, Du Q, Chen J, Luo L, Lindblom A. Hereditary breast cancer: a review. Semin Cancer Biol. 2000 Aug;10(4):271-88. doi: http://dx.doi.org/10.1006/scbi.2000.0325
42. Bertram JS. The molecular biology of cancer. Mol Aspects Med. 2000 Dec;21(6):167-223.
43. Berx G, Van Roy F. The-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3(5):289-93.
44. Billings CG, Howard P. Asbestos exposure, lung cancer and asbestosis. Monaldi Arch Chest Dis. 2000 Apr;55(2):151-6.
45. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis. 2000 Mar;21(3):405-26.
46. Carico E, Atlante M, Bucci B, Nofroni I, Vecchione A. E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma. Gynecol Oncol. 2001 Feb;80(2):156-61.
47. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001 Jan;344(4):276-85.
48. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg. 1999 Dec;118(6):1136-52. doi: http://dx.doi.org/10.1016/S0022-5223(99)70121-2
49. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov;343(21):1566-8. doi: http://dx.doi.org/10.1056/NEJM200011233432111
50. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan;100(1):57-70.
Information about authors:
PobyarzhinV.V. – Candidate of Biological Sciences, associate professor, doctoral candidate of the Chair of Infectious Diseases, Vitebsk State Order of Peoples’ Friendship Medical University;
Pashinskaya Е.S – Candidate of Biological Sciences, associate professor of the Chair of Medical Biology & General Genetics, Vitebsk State Order of Peoples’ Friendship Medical University;
Semenov V.M. – Doctor of Medical Sciences, professor, head of the Chair of Infectious Diseases, Vitebsk State Order of Peoples’ Friendship Medical University;
Dmitrachenko T.I. – Doctor of Medical Sciences, professor of the Chair of Infectious Diseases, Vitebsk State Order of Peoples’ Friendship Medical University;
Shlyakhtunov E.A. – Candidate of Medical Sciences, associate professor of the Chair of Oncology with the courses of Radiation Diagnosing & Radiation Therapy of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210023, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Infectious Diseases. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Pobyarzhin Vyacheslav V.
